0
2021
Central Nervous Disorders Therapeutics Market

Central Nervous Disorders Therapeutics Market

by Disease (Neurovascular Diseases, Degenerative Diseases, Infectious Diseases, Mental Health, and Others, Distribution Channel (Hospital-Based Pharmacies, Retail Pharmacies, and Online Pharmacies), and Age Group (Pediatric, Adult, and Geriatric): Global Opportunity Analysis and Industry Forecast, 2021-2030
Update Available On-Demand

Report Code: A13121
Pages: 274
Aug 2021 | 1309 Views
Author(s) : Apoorva Srivastava , Onkar Sumant
Tables: 119
Charts: 55
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Central Nervous Disorders Therapeutics Market

Request Now !

The central nervous disorders therapeutics market generated $1,17,556.10 million in 2020, and is projected to reach $2,32,294.20 million by 2030, growing at a CAGR of 7.3% from 2021 to 2030.

Central nervous system is a part of the nervous system, which controls most functions of the body and mind. It consists of two parts, brain, and spinal cord. It integrates the received information, thereafter, coordinating and controlling activities of all parts of the body. However, central nervous system disorders include neurovascular diseases, degenerative diseases, infectious diseases, mental health, and other diseases, which affect structure and function of brain or spinal cord. Thus, CNS treatment is used to treat these disorders. In addition, the central nervous disorders therapeutics market is anticipated to grow substantially during the forecast period, owing to increase in geriatric population and rise in case of CNS disorders such as neurovascular diseases, degenerative diseases, Alzheimer's disease, Parkinson's disease, multiple sclerosis, infectious diseases, mental health, anxiety disorders, bipolar disorder, and depression.

Central-Nervous-Disorders-Therapeutics-Market

Moreover, increase in demand for effective CNS treatment and therapeutic options encourages major pharmaceutical companies to invest in R&D, which creates future growth opportunities. Furthermore, rise in R&D activities for introduction of novel drugs and advancements in diagnostics technologies to develop superior drug delivery system are anticipated to propel the market for central nervous system disorder treatment.

In addition, rise in prevalence of CNS disorders and presence of strong pipeline drugs are the major factors that drive growth of the central nervous disorders therapeutics market. However, high treatment cost hampers the market growth, especially high cost of treatment in developing countries. Moreover, introduction of a novel drug delivery systems in CNS and advancements in technologies to develop superior drug delivery systems are expected to create future growth opportunities for the central nervous disorders therapeutics market.

COVID-19 impact on the central nervous disorders therapeutics market

Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. 

After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement.

Furthermore, the virus has high potential of lethality in geriatric population. On 11th March 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, there are only a few vaccines that received emergency approvals for COVID-19 treatment or prevention. Thus, social-distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns. Most markets are experiencing a decline, owing to the outbreak. This also includes the central nervous disorders therapeutics market. In addition, COVID-19 severely affects the respiratory system and it has been reported to show effects on central and peripheral systems. This included encephalopathy, inflammation, ischemic stroke, and peripheral neurological disorders. Moreover, patients suffering from severe illness from COVID-19 have neurologic manifestations of acute cerebrovascular disease, impaired consciousness, and skeletal muscle injury. According to the National Center for Biotechnology Information (NCBI), data published in 2020, states that patients with pneumonia typically develop hypoxic or type 1 respiratory failure, with low CO2 levels and a raised respiratory rate, while brain failure typically leads to type 2 respiratory failure and involves low oxygen, high CO2 and reduced respiratory rate. In addition, COVID-19 may have minimal impact on the central nervous disorders therapeutics market.

Central Nervous Disorders Therapeutics Market Segmentation

The central nervous disorders therapeutics market is classified on the basis of disease, distribution channel, age group, and region. By disease, the market is divided into neurovascular diseases, degenerative diseases (Alzheimer's diseases, Parkinson's disease, multiple sclerosis, and others), infectious diseases, mental health (anxiety disorders, bipolar disorder, depression, and others), and other diseases. By distribution channel, it is categorized into hospital-based pharmacies, retail pharmacies, and online pharmacies. By age group, it is segmented into pediatric, adult, and geriatric. By region, the market is analyzed across, North America, Europe, Asia-Pacific, and LAMEA.

Segment review

By disease, the degenerative disease segment accounted for the largest share in the central nervous disorders therapeutics market in 2020. In addition, this segment is expected to maintain its position during the forecast period. Key factors, such as increase in geriatric population, which is prone to CNS disorder including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other diseases are set to drive growth of the market. 

Central Nervous Disorders Therapeutics Market
By Disease

Your browser does not support the canvas element.

Mental Health segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By distribution channel, the hospital-based pharmacies segment accounted for a major share of the market share in the central nervous disorders therapeutics market in 2020. This segment is expected to exhibit a prominent growth rate, owing to rapid increase of central nervous system disorder rate in geriatric population, technological advancements, and lifestyle change, which augments the market growth. 

Central Nervous Disorders Therapeutics Market
By Distribution Channel

Your browser does not support the canvas element.

Retail Pharmacies segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By age group, the geriatric age group segment contributed for a large share in 2020, which was accounted for three-fifths of the total market share. In addition, this segment is expected to maintain its position during the forecast period.

Central Nervous Disorders Therapeutics Market
By Age Group

Your browser does not support the canvas element.

Adult segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By region, the market is divided into North America, Europe, Asia-Pacific, and LAMEA. The North America dominated the market for central nervous system disorder treatment and held the largest revenue share in 2020, with highest growth rate majorly due to changing lifestyle conditions, increase in geriatric population, and increase in cases of central nervous system disorder. 

Central Nervous Disorders Therapeutics Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

Key players operating in the central nervous disorders therapeutics market include Biogen, Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Merck & Co., Astra Zeneca, Shire PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc. and Pfizer, Inc. 

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the central nervous disorders therapeutics market, and the current trends and future estimations to elucidate the imminent investment pockets. 
  • It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Key Market Segments

By Disease

  • Neurovascular Diseases    
    • Degenerative Diseases    
    • Alzheimer's Disease
    • Parkinson's Disease
    • Multiple Sclerosis
    • Others
  • Infectious Diseases    
    • Mental Health    
    • Anxiety Disorders
    • Bipolar Disorder
    • Depression
    • Others
  • Other Diseases

By Distribution Channel

  • Hospital Based Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Age Group

  • Pediatric
  • Adult
  • Geriatric

By Region 

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

List of key players profiled in the report

  • Biogen
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Merck & Co.
  • Astra Zeneca
  • Shire PLC
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc. 
 

Loading Table Of Content...


 
 

This section provides opinions of the top-level CXOs in the central nervous system disorder treatment industry. According to the CXOs, central nervous system disorder that affects the structure and function of the brain and spinal cord and cause diseases and disturbs mental health in population of all age group, mostly in geriatric population.  Diseases such as neurodegenerative diseases, degenerative diseases, Alzheimer’s disease, Parkinson's disease, multiple sclerosis, autoimmune & inflammatory diseases, genetic disorders, tumors, and cancers are disorders of central nervous system that boost the market growth. The degenerative disease segment dominated in 2020, and is expected to remain dominant throughout the forecast period.

According to CXOs, the central nervous system disorder treatment market is anticipated to witness considerable growth in the future, owing to rise in awareness regarding neurovascular diseases, degenerative diseases, infectious diseases, and mental health by government and non-government organizations and surge in prevalence of lifestyle-associated CNS disorders boost growth of the central nervous system disorder treatment market. Moreover, key pharmaceutical players are focusing on new therapies to prevent or improve symptoms of neurological disorders and various other key players in the central nervous system disorder treatment market are heavily investing and launching novel drugs, which is anticipated to boost the market for central nervous system during the forecast period.

CXOs further stated that growth in geriatric population and increase in disorders in emerging countries such as some part of Asia, owing to less neurologic training centres and availability of laboratory facilities and equipment that limited in emerging countries are expected to present lucrative opportunities for the market expansion.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of central nervous system disorders treatment market is $1,17,556.10 million in 2020

A. The forecast period in the report is from 2021 to 2030

A. The market value of central nervous system disorders treatment Market in 2020 was $1,17,556.10 Million

A. The base year for the report is 2020

A. Yes, central nervous system disorders treatment companies are profiled in the report

A. The top companies that hold the market share in central nervous system disorders treatment Market are Biogen, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Merck & Co.. Astra Zeneca, Shire PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc. and Pfizer, Inc.

A. The key trends in the central nervous system disorders treatment Market are increasing prevalence of CNS disorders and presence of strong pipeline drugs are the major factors that drive the growth of the central nervous system disorder treatment market .

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
Central Nervous Disorders Therapeutics Market

Start reading instantly.
This Report and over 18,758+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Aug 2022 - Aug 2023)
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2022 - Aug 2023)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2022 - Aug 2023)
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2022 - Aug 2023)
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2022 - Aug 2023)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers